RESUMEN
Onchocerciasis caused by Onchocerca volvulus Leuckart, 1893 is the second-world infection responsible for human blindness. Except Ivermectin which has as targets the microfilariae of that parasite, specific treatment for this disease does not exist and in developing countries, medicinal plants seem to remedy that health problem. For that, aqueous and hydro-ethanolic leaf, bark, and root extracts of Calotropis procera and Faidherbia albida were evaluated in vitro, against the most popular bovine model, Onchocerca ochengi and the free-resistant nematode Caenorhabditis elegans. O. ochengi microfilariae and adults extracted from the bovine nodules and skins as well as the free strains of C. elegans were exposed to the various concentrations of the plant parts extracts and Ivermectin. In results, all the plant parts extracts were rich in tannins, saponins, alkaloids, flavonoids, phenols, coumarins, and glycosides. Phenols (175.45 ± 0.01 mg EGA/g DM), flavonoids (158.98 ± 0.05 mg EC/g DM), and tannins (89.98 ± 2.56 mg ETA/g DM) contents were high in the bark hydro-ethanolic extract of F. albida. The leaf hydro-ethanolic extract of F. albida induced high activity against O. ochengi microfilariae (CL50 = 0.13 mg/mL). The bark hydro-ethanolic extract of F. albida was also the most effective on O. ochengi adults and particularly on female adults (CL50 = 0.18 mg/mL). Against the parasite strain resistant to Ivermectin, F. albida leaf hydro-ethanolic extract appeared more active with CL50 = 0.13 mg/mL. Similarly, the bark hydro-ethanolic extract of F. albida was the most potent on the wild strain of C. elegans. Thus, this study validates the use of these plants by traditional healers in the management of onchocerciasis and suggests a new source of isolation of the potential plant compounds against Onchocerca.
RESUMEN
Alzheimer's disease is first characterised by memory loss related to the central cholinergic system alteration. Available drugs provide symptomatic treatment with known side effects. The present study is aimed to evaluate the properties of Carissa edulis aqueous extract on a Scopolamine mouse model as an attempt to search for new compounds against Alzheimer's disease-related memory impairment. Memory impairment was induced by administration of 1 mg/kg (i.p.) of Scopolamine for 7 days, and mice were treated with Carissa edulis aqueous extract. Behavioural studies were performed using T-maze and novel object recognition task for assessing learning and memory and open field test for locomotion. Brain acetylcholinesterase enzyme (AChE) activity was measured to evaluate the central cholinergic system. The level of MDA, glutathione, and catalase activity were measured to evaluate the oxidative stress level. Administration of Scopolamine shows a decrease in learning and memory enhancement during behavioural studies. A significant decrease in the time spent in the preferred arm of T-maze, in the time spent in the exploration of the novel object, and in the discrimination index of the familiar object was also observed. The significant impairment of the central cholinergic system was characterised in mice by an increase of AChE activity to 2.55 ± 0.10 mol/min/g with an increase in oxidative stress. Treatment with the different doses of Carissa edulis (62.8, 157, 314, and 628 mg/kg orally administrated) significantly increased the memory of mice in T-maze and novel object recognition tests and also ameliorated locomotion of mice in the open field. Carissa edulis aqueous extract treatment also decreases the AChE activity and brain oxidative stress. It is concluded that administration of Carissa edulis aqueous extract enhances memory of mice by reducing AChE activity and demonstrating antioxidant properties. This could be developed into a novel therapy against memory impairment related to Alzheimer's disease.